Adavosertib: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Adavosertib == | |||
[[File:Adavosertib.svg|thumb|right|Chemical structure of Adavosertib]] | |||
'''Adavosertib''' is a small molecule inhibitor of the [[WEE1]] kinase, which plays a crucial role in the regulation of the [[cell cycle]]. It is being investigated for its potential use in the treatment of various types of [[cancer]]. | |||
Adavosertib | |||
== | === Mechanism of Action === | ||
Adavosertib functions by inhibiting the activity of the WEE1 kinase. WEE1 is a key regulator of the [[G2/M checkpoint]] in the cell cycle. By inhibiting WEE1, adavosertib prevents the phosphorylation of [[cyclin-dependent kinase 1]] (CDK1), leading to the premature entry of cells into [[mitosis]]. This can result in [[mitotic catastrophe]] and [[apoptosis]] in cancer cells, particularly those with defective [[p53]] pathways. | |||
== | === Clinical Development === | ||
Adavosertib is currently undergoing clinical trials for its efficacy in treating various cancers, including [[ovarian cancer]], [[breast cancer]], and [[colorectal cancer]]. It is often studied in combination with other chemotherapeutic agents to enhance its anticancer effects. | |||
=== Pharmacokinetics === | |||
The pharmacokinetic profile of adavosertib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys. | |||
=== Side Effects === | |||
Common side effects of adavosertib include [[nausea]], [[diarrhea]], [[fatigue]], and [[hematological toxicity]]. These side effects are generally manageable with supportive care and dose adjustments. | |||
== Related Pages == | |||
* [[WEE1 kinase]] | * [[WEE1 kinase]] | ||
* [[Cell cycle]] | * [[Cell cycle]] | ||
* [[Cancer treatment]] | * [[Cancer treatment]] | ||
* [[ | * [[Apoptosis]] | ||
[[Category: | [[Category:Anticancer drugs]] | ||
[[Category: | [[Category:Cell cycle inhibitors]] | ||
Latest revision as of 03:54, 13 February 2025
Adavosertib[edit]
Adavosertib is a small molecule inhibitor of the WEE1 kinase, which plays a crucial role in the regulation of the cell cycle. It is being investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
Adavosertib functions by inhibiting the activity of the WEE1 kinase. WEE1 is a key regulator of the G2/M checkpoint in the cell cycle. By inhibiting WEE1, adavosertib prevents the phosphorylation of cyclin-dependent kinase 1 (CDK1), leading to the premature entry of cells into mitosis. This can result in mitotic catastrophe and apoptosis in cancer cells, particularly those with defective p53 pathways.
Clinical Development[edit]
Adavosertib is currently undergoing clinical trials for its efficacy in treating various cancers, including ovarian cancer, breast cancer, and colorectal cancer. It is often studied in combination with other chemotherapeutic agents to enhance its anticancer effects.
Pharmacokinetics[edit]
The pharmacokinetic profile of adavosertib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys.
Side Effects[edit]
Common side effects of adavosertib include nausea, diarrhea, fatigue, and hematological toxicity. These side effects are generally manageable with supportive care and dose adjustments.
